ClinicalTrials.gov
public full text
Public Domain
Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans
The purpose of this study is to determine the dose of the GLP-1 receptor antagonist exendin(9-39) which blocks the insulinotropic action of synthetic GLP-1 by at least 95%.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- GLP-1 Receptor Targeting in Diabetic and Healthy Individuals#802403
- Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus#1010732
- Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin#1261096
- Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins#835370
- Effect of GLP-1 Receptor Agonists on Trabecular Bone Score#1371100
Record · ID 1365336
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive